Akero Therapeutics, Inc. (AKRO) Financial Statements (2024 and earlier)

Company Profile

Business Address 601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:351,449,000188,258,000268,387,000136,400,000
Cash and cash equivalents249,773,000150,483,000187,242,00064,788,000
Short-term investments393,852,000191,811,000320,313,000196,865,000
Other undisclosed cash, cash equivalents, and short-term investments(292,176,000)(154,036,000)(239,168,000)(125,253,000)
Deferred costs  524,00046,000 
Other undisclosed current assets3,724,0004,800,0002,912,0001,649,000
Total current assets:355,173,000193,582,000271,345,000138,049,000
Noncurrent Assets
Operating lease, right-of-use asset1,242,0001,459,0001,662,000 
Property, plant and equipment47,00090,000131,000 
Long-term investments and receivables    
Long-term investments    
Other noncurrent assets 108,000417,000201,00069,000
Total noncurrent assets:1,397,0001,966,0001,994,00069,000
TOTAL ASSETS:356,570,000195,548,000273,339,000138,118,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,969,0007,384,0004,077,0002,923,000
Employee-related liabilities554,000495,0001,606,000
Accounts payable7,968,0006,706,0003,428,000947,000
Accrued liabilities1,001,000124,000154,000370,000
Debt    
Other liabilities    85,000
Other undisclosed current liabilities10,114,00017,744,0009,034,0006,361,000
Total current liabilities:19,083,00025,128,00013,111,0009,369,000
Noncurrent Liabilities
Long-term debt and lease obligation9,541,0001,311,0001,516,000 
Long-term debt, excluding current maturities9,541,000   
Liabilities, other than long-term debt1,384,000  23,000
Other liabilities    23,000
Operating lease, liability1,079,0001,311,0001,516,000 
Derivative instruments and hedges, liabilities305,000   
Other undisclosed noncurrent liabilities  (1,311,000)(1,516,000) 
Total noncurrent liabilities:10,925,0001,311,0001,516,00023,000
Total liabilities:30,008,00026,439,00014,627,0009,392,000
Equity
Equity, attributable to parent326,562,000169,109,000258,712,000128,726,000
Common stock5,0004,0004,0003,000
Additional paid in capital748,857,000479,436,000468,238,000259,049,000
Accumulated other comprehensive income (loss)37,000(27,000)(3,000)(6,000)
Accumulated deficit(422,337,000)(310,304,000)(209,527,000)(130,320,000)
Total equity:326,562,000169,109,000258,712,000128,726,000
TOTAL LIABILITIES AND EQUITY:356,570,000195,548,000273,339,000138,118,000

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating expenses(115,156,000)(100,886,000)(80,154,000)(45,651,000)
Operating loss:(115,156,000)(100,886,000)(80,154,000)(45,651,000)
Nonoperating income3,846,000104,000947,0001,896,000
Other nonoperating income3,862,000109,000947,0001,896,000
Interest and debt expense(739,000)   
Loss from continuing operations before income taxes:(112,049,000)(100,782,000)(79,207,000)(43,755,000)
Income tax expense (benefit)  (30,626,000)20,715,000(24,000)
Loss from continuing operations:(112,049,000)(131,408,000)(58,492,000)(43,779,000)
Loss before gain (loss) on sale of properties:(131,408,000)(58,492,000)(43,779,000)
Other undisclosed net income (loss)16,00030,631,000(20,715,000)24,000
Net loss available to common stockholders, diluted:(112,033,000)(100,777,000)(79,207,000)(43,755,000)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(112,033,000)(100,777,000)(79,207,000)(43,755,000)
Comprehensive loss:(112,033,000)(100,777,000)(79,207,000)(43,755,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent64,000(24,000)3,000(6,000)
Comprehensive loss, net of tax, attributable to parent:(111,969,000)(100,801,000)(79,204,000)(43,761,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: